Zimbabwe: Zimbabwe Faces New Challenge in HIV Treatment As Resistance to Dolutegravir (DTG) Emerges

[263Chat] Zimbabwe’s remarkable progress in HIV treatment faces a new hurdle as cases of resistance to the life-saving drug, Dolutegravir (DTG), emerge. With over 1.2 million people currently on Antiretroviral Therapy (ART), accounting for approximately 90% of those living with HIV, the country’s achievements in combating the disease are significant. However, the increasing instances of DTG resistance pose a considerable threat to the nation’s hard-won gains.



Source link : https://allafrica.com/stories/202411140050.html

Author :

Publish date : 2024-11-14 05:43:00

Copyright for syndicated content belongs to the linked Source.